Extended Data Table 5 Change from baseline in metabolic factors at Week 52 (safety population)

From: Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

  1. CFB, change from baseline; CI, confidence interval; DB, double-blind; DBP, diastolic blood pressure; ECG, electrocardiogram; LSM, least squares mean; NA, not available; OL, open-label; SEM, standard error of the mean; SBP, systolic blood pressure; SE, standard error.
Back to article page